MARKET

CYAD

CYAD

Celyad Oncology
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.60
-0.13
-1.68%
Closed 16:00 03/03 EST
OPEN
7.61
PREV CLOSE
7.73
HIGH
7.71
LOW
7.50
VOLUME
4.26K
TURNOVER
--
52 WEEK HIGH
13.01
52 WEEK LOW
4.100
MARKET CAP
105.96M
P/E (TTM)
-3.1569
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Celyad Oncology Announces March 2021 Conference Schedule
MONT-SAINT-GUIBERT, Belgium, March 01, 2021 (GLOBE NEWSWIRE) -- Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell ...
GlobeNewswire · 2d ago
At 34.5% CAGR, CAR-T Cell Therapy Market Size, Share and Analysis to reach $ 8.92 billion by 2026
Feb 23, 2021 (Market Insight Reports) -- Selbyville, Delaware. The report CAR-T Cell Therapy Market Size and Analysis maintains enhanced dynamics and is...
Market Insight Reports · 02/23 10:42
Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Share, Size ,Growth Opportunities, Global Competition Strategies, Statistics, Industry Trends, Revenue Analysis, Key Players, Regional Analysis by Forecast to 2025
Feb 19, 2021 (The Expresswire) -- Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Research report discusses the market growth drivers and...
The Express Wire · 02/19 05:54
Celyad (CYAD) Gets a Buy Rating from William Blair
William Blair analyst Raju Prasad maintained a Buy rating on Celyad (CYAD) today. The company's shares closed last Friday at $8.14. According to
SmarterAnalyst · 02/16 09:55
Myocardial Infarction Drug Market 2021 SWOT Analysis, Key Business Strategies, Leading Industry Players, Regional Growth, Demand, Share, Challenges, Opportunities and 2027 Forecast Research Report
Feb 16, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry.” The global “Myocardial Infarction Drug...
The Express Wire · 02/16 07:01
The T-cell immunotherapy market is projected to grow at an annualized rate of 12.2%, claims Roots Analysis
London, Feb 11, 2021 (GLOBE NEWSWIRE via COMTEX) -- London, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of "Global T-Cell...
GlobeNewswire · 02/11 17:03
The Europe cell and gene therapy market by revenue is expected to grow at a CAGR of over 23% during the period 2021-2026
New York, Feb 10, 2021 (GLOBE NEWSWIRE via COMTEX) -- New York, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report...
GlobeNewswire · 02/10 12:35
Stem Cell Reconstructive Market Size 2021 By Analysis, Manufacturers, Regions, Type and Application, and Forecasts to 2023
Heraldkeepers · 02/08 16:11
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CYAD. Analyze the recent business situations of Celyad Oncology through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CYAD stock price target is 17.52 with a high estimate of 19.84 and a low estimate of 14.88.
EPS
Institutional Holdings
Institutions: 14
Institutional Holdings: 829.95K
% Owned: 5.95%
Shares Outstanding: 13.94M
TypeInstitutionsShares
Increased
0
0
New
2
-12.58K
Decreased
4
47.72K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.96%
Pharmaceuticals & Medical Research
-1.89%
Key Executives
Chairman/Co-Founder/Director
Michel Lussier
Chief Executive Officer/Executive Director/Executive Board
Christian Homsy
Chief Financial Officer/Executive Board/Primary Contact
Patrick Jeanmart
Chief Operating Officer
Gaetane Metz
Vice President
Richard Mountfield
Vice President - Research & Development/Executive Board
Peter De Waele
Vice President - Business Development
Georges Rawadi
Other
Seron Aymeric
Other
Philippe Dechamps
Other
Roland Gordon-Beresford
Non-Executive Director
Serge Goblet
Non-Executive Director
Hanspeter Spek
Non-Executive Director
William Wijns
Independent Director
Chris Buyse
Independent Director
Rudy Dekeyser
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
No Data
About CYAD
Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company's product, C-Cure, allows the differentiation of a patient's own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle. C-Cure consists of autologous adult stem cells guided in vitro to the cardiac lineage before implantation in the failing heart. Furthermore, the Company is involved in the field of immuno-oncology, through its subsidiary, OnCyte.

Webull offers kinds of Celyad Oncology stock information, including NASDAQ:CYAD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYAD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CYAD stock methods without spending real money on the virtual paper trading platform.